Novo Nordisk's CagriSema Achieves Average Weight Loss of 25% in Women
A phase 3 trial conducted by Novo Nordisk (NVO) showed that its experimental drug, CagriSema—a combination of cagrilintide and semaglutide—led to an average weight loss of 25% among overweight or obese women after 68 weeks. The study included over 2300 participants, making it a significant trial in the field of obesity treatment. The results highlight CagriSema's potential as a groundbreaking therapy for weight management and could position Novo Nordisk at the forefront of pharmaceutical innovation in this space. These findings may influence investor sentiment toward the company due to their implications on future revenue streams from new drug approvals.
Tickers: $NVO
Topics: clinical trial pharmaceuticals weight loss
Read the full article at Seeking Alpha
Part of the story Novo Nordisk's CagriSema Shows 25% Weight Loss in Phase 3 Clinical Trial (3 articles)